Search results for "copd"

showing 10 items of 483 documents

Hsp60 and Hsp10 down-regulation predicts bronchial epithelial carcinogenesis in smokers with chronic obstructive pulmonary disease.

2006

BACKGROUND. The relation between smoking, chronic obstructive pulmonary disease (COPD), and lung cancer (LC) is an open field of investigation. A higher frequency of adenocarcinoma has been reported in patients with COPD. Heat shock proteins (Hsps) are implicated in tumoral cell growth and differentiation. The aim of the present study was to investigate the expression of Hsp60 and Hsp10 in bronchial biopsies from smokers with COPD and in 10 lung cancer patients and to evaluate the association between Hsps expression and carcinogenetic steps of LC. METHODS. An immunohistochemical study was performed for Hsp60 and Hsp10 in bronchial biopsies from 35 COPD (postbronchodilator forced expiratory …

Cancer ResearchPathologymedicine.medical_specialtyLung NeoplasmsAdenosquamous carcinomaBlotting WesternDown-Regulationchemical and pharmacologic phenomenaRespiratory MucosaAdenocarcinomaCarcinoma AdenosquamousPulmonary Disease Chronic ObstructivemedicineChaperonin 10HumansLung cancerAgedsmoking chaperone expression lung obstruction lung tumorsCOPDSettore BIO/16 - Anatomia Umanabusiness.industryRespiratory diseaseSmokingCancerChaperonin 60Middle Agedmedicine.diseasePrognosisSquamous metaplasiarespiratory tract diseasesCarcinoma BronchogenicOncologyDysplasiaDisease ProgressionAdenocarcinomabusinessCancer
researchProduct

β2long-acting and anticholinergic drugs synergistically control TGFβ1-mediated neutrophilic inflammation in COPD: an “in vitro” model.

2011

TGFβ1 is involved in airway inflammation in COPD and in the regulation of muscarinic receptors (mAChRs) expression. We quantified TGFβ1 and Acetylcholine (ACh) concentrations in induced sputum supernatants (ISs) from 10 Healthy Controls (HC), 14 Healthy Smokers (HS) and 16 COPDs. We tested: 1) ISs from HC, HS and COPD on neutrophil adhesion to human bronchial epithelial cells (16HBE) in the presence or absence of an anti-TGFβ1ab or Olodaterol (β2-adrenoceptor agonist) and Tiotropium (Spiriva®) alone or in combination; 2) ISs from COPD on mAChRs expression in 16HBE in the presence or absence of anti-TGFβ1-antibody and Olodaterol; 3) hrTGFβ1on neutrophil adhesion and mChRs and ChAT expression…

Cell biology COPD - management Epithelial cell
researchProduct

The role of cefditoren in the treatment of lower community-acquired respiratory tract infections (LRTIs): from bacterial eradication to reduced lung …

2014

Lower respiratory tract infections (LRTIs), including pneumonia and acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD), are among the most common diagnoses in both outpatient and inpatient settings. Due to the burden of LRTIs healthcare providers must adopt practices focused on improving outcomes with the aim to reduce treatment failure and antibiotic resistances. Moreover, the role of acute and chronic infection in the pathogenesis of COPD has received considerable attention, since chronic infection can contribute to airways inflammation and COPD progression. This review discusses the role of cefditoren for the treatment of LRTIs, compared with the definition of "appropria…

Chronic ObstructiveDose-Response Relationship DrugDrug ResistanceBacterialMicrobial Sensitivity TestsPneumoniaSettore MED/10 - Malattie Dell'Apparato RespiratorioAnti-Bacterial AgentsCephalosporinsCommunity-Acquired InfectionsDose-Response RelationshipPulmonary DiseasePulmonary Disease Chronic ObstructiveDrug Resistance Multiple BacterialPneumonia BacterialDisease ProgressionHumansAnti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Disease Eradication; Disease Progression; Dose-Response Relationship Drug; Drug Resistance Multiple Bacterial; Humans; Microbial Sensitivity Tests; Pneumonia Bacterial; Pulmonary Disease Chronic ObstructiveDisease EradicationDrugantibiotics outpatients COPDMultiple
researchProduct

High-flow nasal therapy versus noninvasive ventilation in COPD patients with mild-to-moderate hypercapnic acute respiratory failure: study protocol f…

2019

Background Noninvasive ventilation (NIV) is indicated to treat respiratory acidosis due to exacerbation of chronic obstructive pulmonary disease (COPD). Recent nonrandomized studies also demonstrated some physiological effects of high-flow nasal therapy (HFNT) in COPD patients. We designed a prospective, unblinded, multicenter, randomized controlled trial to assess the noninferiority of HFNT compared to NIV with respect to the reduction of arterial partial pressure of carbon dioxide (PaCO2) in patients with hypercapnic acute respiratory failure with mild-to-moderate respiratory acidosis. Methods We will enroll adult patients with acute hypercapnic respiratory failure, as defined by arterial…

Chronic ObstructiveTime FactorsExacerbationRespiratory ratemedicine.medical_treatmentMedicine (miscellaneous)Equivalence Trials as TopicAcute respiratory failurelaw.inventionPulmonary DiseaseHypercapnia03 medical and health sciencesPulmonary Disease Chronic ObstructiveStudy Protocol0302 clinical medicineAcute respiratory failure; Carbon dioxide; Chronic obstructive pulmonary disease; Emergency department; High-flow oxygen therapy through nasal cannula; Intensive care unit; Noninvasive ventilation; Acute Disease; Equivalence Trials as Topic; Humans; Hypercapnia; Italy; Lung; Multicenter Studies as Topic; Oxygen Inhalation Therapy; Prospective Studies; Pulmonary Disease Chronic Obstructive; Respiratory Insufficiency; Time Factors; Treatment Outcome; Noninvasive VentilationRandomized controlled triallawHigh-flow oxygen therapy through nasal cannulamedicineHumansMulticenter Studies as TopicPharmacology (medical)Intensive care unit030212 general & internal medicineProspective StudiesLungTidal volumeMechanical ventilationCOPDlcsh:R5-920business.industryEmergency departmentChronic obstructive pulmonary diseaseOxygen Inhalation Therapymedicine.diseaseIntensive care unitRespiratory acidosisTreatment OutcomeItalyCarbon dioxideAnesthesiaAcute DiseasebusinessRespiratory Insufficiencylcsh:Medicine (General)Acute respiratory failure; Carbon dioxide; Chronic obstructive pulmonary disease; Emergency department; High-flow oxygen therapy through nasal cannula; Intensive care unit; Noninvasive ventilationNoninvasive ventilation030217 neurology & neurosurgeryTrials
researchProduct

Clinical Evolution and Quality of Life in Clinically Based COPD Chronic Bronchitic and Emphysematous Phenotypes: Results from the 1-Year Follow-Up of…

2021

Francesco Blasi, 1, 2 Raffaele Antonelli Incalzi, 3 Giorgio Walter Canonica, 4 Pietro Schino, 5 Giuseppina Cuttitta, 6 Alessandro Zullo, 7 Alessandra Ori, 7 Nicola Scichilone 8 On behalf of STORICO study group 1Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, 20122, Italy; 2Department of Pathophysiology and Transplantation, University of Milan, Milan, 20122, Italy; 3University Biomedical Campus of Rome, Rome, 00128, Italy; 4Personalized Medicine Asthma & Allergy Clinic Humanitas University Humanitas research Hospital Rozzano, Rozzano (Milan), 20089, Italy; 5Miulli Hospital, Acquaviva …

Chronic bronchitismedicine.medical_specialtySettore MED/10 - Malattie Dell'Apparato RespiratorioDiseases of the respiratory systemPulmonary Disease Chronic ObstructiveClinical evolution Clinical phenotype COPD Quality of life Follow-Up Studies Humans Phenotype Quality of Life Bronchitis Chronic Emphysema Pulmonary Disease Chronic Obstructive ItalyQuality of lifeDLCOInternal medicinemedicineHumansCOPDDepression (differential diagnoses)Original ResearchEmphysemaclinical evolutionCOPDRC705-779business.industryMinimal clinically important differenceGeneral Medicineclinical phenotypemedicine.diseaseBronchitis ChronicPulmonologyPhenotypeItalyquality of lifeAnxietymedicine.symptombusinessFollow-Up StudiesInternational journal of chronic obstructive pulmonary disease
researchProduct

Determinants of between-hospital variations in outcomes for patients admitted with COPD exacerbations: findings from a nationwide clinical audit (AUD…

2015

Background Previous studies have demonstrated significant variability in the processes of care and outcomes of chronic obstructive pulmonary disease (COPD) exacerbations. The AUDIPOC is a Spanish nationwide clinical audit that identified large between-hospital variations in care and clinical outcomes. Here, we test the hypothesis that these variations can be attributed to either patient characteristics, hospital characteristics and/or the so-called hospital-clustering effect, which indicates that patients with similar characteristics may experience different processes of care and outcomes depending on the hospital to which they are admitted. Methods A clinical audit of 5178 COPD patients co…

Clinical auditMalePediatricsmedicine.medical_specialtyPulmonologymedia_common.quotation_subjectPsychological interventionMEDLINEPulmonary diseaseDisease clusterPatient ReadmissionAUDIPOCPulmonary Disease Chronic ObstructivemedicineOdds RatioHumansHospital Mortalitymedia_commonAgedOriginal PaperCOPDVariablesClinical Auditbusiness.industryHospitals PublicGeneral MedicineOdds ratioMiddle Agedmedicine.diseasePrognosisCOPD exacerbationsSpainEmergency medicineFemalebusiness
researchProduct

[Clinical audit of patients admitted to hospital in Spain due to exacerbation of COPD (AUDIPOC study): method and organisation].

2010

There is little information regarding the clinical management of hospital inpatients diagnosed with exacerbation of Chronic Obstructive Pulmonary Disease (COPD). AUDIPOC is a clinical audit dealing with the clinical management of COPD in Spain.To examine the adequacy and validity of the instruments used to measure the variables proposed by AUDIPOC Spain (Preliminary Study) and to verify the viability of AUDIPOC in a complex environment with hospitals of different sizes, resources, and organizational layout (Pilot Study).The Preliminary Study took place in 4 hospitals and studied 213 cases. The Pilot Study took place in 30 hospitals of 6 Autonomous Communities (i.e. Regions) and studied 1203…

Clinical auditMalemedicine.medical_specialtyExacerbationPulmonary diseasePilot ProjectsPulmonary Disease Chronic ObstructivePatient AdmissionCatchment Area HealthmedicineHumansMulticenter Studies as TopicProspective StudiesIntensive care medicineCOPDMedical Auditbusiness.industryHospitals PublicGeneral Medicinemedicine.diseaserespiratory tract diseasesHospitalizationCross-Sectional StudiesResearch DesignSpainFemalebusinessFollow-Up StudiesArchivos de bronconeumologia
researchProduct

Patients in clinical trials on COPD triple therapy compared to real world populations

2019

Clinical trialCOPDmedicine.medical_specialtybusiness.industryInternal medicinemedicinemedicine.diseasebusiness61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.
researchProduct

Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease

2013

Background Glucocorticoid functions are markedly impaired in patients with chronic obstructive pulmonary disease (COPD). The phosphodiesterase 4 inhibitor roflumilast N-oxide (RNO) is the active metabolite of roflumilast approved as a treatment to reduce the risk of exacerbations in patients with severe COPD. Objective We sought to characterize the differential effects of RNO versus corticosteroids and their potential additive/synergistic effect in neutrophils from patients with COPD, thus providing scientific rationale for the combination of roflumilast with corticosteroids in the clinic. Methods Peripheral blood neutrophils were isolated from patients with COPD (n = 32), smokers (n = 7), …

CyclopropanesLipopolysaccharidesMaleMAPK/ERK pathwaymedicine.medical_specialtyNeutrophilsPrimary Cell CultureImmunologyDrug ResistanceAminopyridinesGene ExpressionComplex MixturesDexamethasoneHistone DeacetylasesPhosphatidylinositol 3-KinasesPulmonary Disease Chronic ObstructiveGlucocorticoid receptorAdrenal Cortex HormonesInternal medicineTobaccomedicineHumansImmunology and AllergyMacrophage Migration-Inhibitory FactorsDexamethasoneActive metaboliteRoflumilastAgedCOPDbusiness.industryInterleukin-8Drug SynergismMiddle Agedmedicine.diseaseIntramolecular OxidoreductasesEndocrinologyMatrix Metalloproteinase 9BenzamidesMitogen-Activated Protein Kinase PhosphatasesFemaleMacrophage migration inhibitory factorPhosphodiesterase 4 InhibitorsbusinessBiomarkersGlucocorticoidmedicine.drugJournal of Allergy and Clinical Immunology
researchProduct

Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist

2015

Chronic obstructive pulmonary disease (COPD) is characterised by chronic pulmonary inflammation punctuated by periods of viral exacerbations. Recent evidence suggests that the combination of roflumilast with corticosteroids may improve the compromised anti-inflammatory properties of corticosteroids in COPD. We analyzed differential and combination anti-inflammatory effects of dexamethasone and roflumilast N-oxide in human bronchial epithelial cells (HBECs) stimulated with viral toll like receptor (TLR) agonists. Lung tissue and HBECs were isolated from healthy (n = 15), smokers (n = 12) and smokers with COPD (15). TLR3 expression was measured in lung tissue and in HBECs. IL-8 secretion was …

CyclopropanesMaleAnti-Inflammatory AgentsDrug ResistanceAminopyridinesDexamethasonePulmonary Disease Chronic ObstructiveRoflimilastAdrenal Cortex HormonesToll like receptorsCells CulturedCOPDSmokingMiddle Agedmedicine.anatomical_structureBenzamidesCorticosteroidViral exacerbationDrug Therapy CombinationFemalePulmones - Enfermedadesmedicine.drugSignal TransductionAgonistPulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classCorticosteroid resistanceBronchiInternal medicinemedicineCOPDHumansInterleukin 8DexamethasoneRoflumilastAgedLungbusiness.industryResearchInterleukin-8Epithelial CellsAparato respiratoriomedicine.diseaserespiratory tract diseasesToll-Like Receptor 3EndocrinologyPoly I-CCase-Control StudiesTLR3businessRespiratory Research
researchProduct